Show simple item record

dc.contributor.authorMu, L.
dc.contributor.authorChan-Park, Mary Bee-Eng
dc.contributor.authorYue, Chee Yoon
dc.contributor.authorFeng, S.S.
dc.date.accessioned2003-12-15T12:00:00Zen_US
dc.date.available2003-12-15T12:00:00Zen_US
dc.date.issued2004-01
dc.identifier.urihttp://hdl.handle.net/1721.1/3916
dc.description.abstractA suitable management of the pharmaceutical property is needed and helpful to design a desired nanoparticulate delivery system, which includes the carrier nature, particle size and size distribution, morphology, surfactant stabiliser according to the technique applied, drug-loading ratio and encapsulation efficiency, surface property, etc. All will influence the in vitro release, in vivo behaviour and tissue distribution of administered particulate drug loaded nanoparticles. The main purpose of the present work was to determine the effect of drug loading ratio when employing TPGS as surfactant stabiliser and/or matrix material to improve the nanoparticulate formulation. The model drug employed was paclitaxel.en
dc.description.sponsorshipSingapore-MIT Alliance (SMA)en
dc.format.extent532760 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoen_US
dc.relation.ispartofseriesInnovation in Manufacturing Systems and Technology (IMST);
dc.subjectbiomaterialsen
dc.subjectdrug deliveryen
dc.subjectsurfactant stabiliseren
dc.subjectPaclitaxelen
dc.subjectD-α -tocopheryl polyethylene glycol 1000 succinate.en
dc.titlePharmaceutical Properties of Nanoparticulate Formulation Composed of TPGS and PLGA for Controlled Delivery of Anticancer Drugen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record